Archives

Health Action International Criticises JURI Support for EU Trade Secrets Directive Report

AMSTERDAM—Health Action International is disappointed that the European Parliament Committee on Legal Affairs (JURI) failed to protect the health of European citizens today by voting to adopt the rapporteur’s report…
HAI Admin
16 June 2015

HAI urges MEPs to support key amendments to TTIP resolution

by TESSEL MELLEMA and ALIÉNOR DEVALIÈRE, EU Policy Advisors (UPDATE at 5:15 p.m. on 9 June: The European Parliament vote on TTIP has been postponed to a later date.) It’s going…
HAI Admin
9 June 2015

How TTIP Could Damage Access to Affordable Medicines in the European Union

What’s the “big deal”? The European Union and United States are negotiating the Transatlantic Trade and Investment Partnership. Under the deal, we’ll pay more for our medicines and know less…
HAI Admin
14 April 2015

How TTIP Could Damage Access to Affordable Medicines in the European Union

What’s the “big deal”? The European Union and United States are negotiating the Transatlantic Trade and Investment Partnership. Under the deal, we’ll pay more for our medicines and know less…
HAI Admin
14 April 2015

EU Trade Secrets Directive Threat to Free Speech, Health, Environment and Worker Mobility

Multi-sectoral civil society coalition calls for greater protections for consumers, journalists, whistleblowers, researchers and workers We strongly oppose the hasty push by the European Commission and Council for a new…
HAI Admin
23 March 2015

Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion

Rational Use of Medicines and Medicines Promotion When medicines are used rationally, patients receive appropriate treatment, in doses that meet their individual requirements, for an adequate period of time. We…
HAI Admin
15 March 2015

Assessing the Nature, Extent and Impact of Regulation of Medicines Promotion

Rational Use of Medicines and Medicines Promotion When medicines are used rationally, patients receive appropriate treatment, in doses that meet their individual requirements, for an adequate period of time. We…
HAI Admin
15 March 2015

EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions

AMSTERDAM—The European Medicines Agency’s (EMA) proposal regarding the specifications of the European Union (EU) clinical trials database can jeopardise the transparency advances obtained through the European Clinical Trials Regulation. We…
HAI Admin
18 February 2015

EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions

AMSTERDAM—The European Medicines Agency’s (EMA) proposal regarding the specifications of the European Union (EU) clinical trials database can jeopardise the transparency advances obtained through the European Clinical Trials Regulation. We…
HAI Admin
18 February 2015

The EU-US Trade Deal Could Leave Europeans Sick

by TESSEL MELLEMA and ALIÉNOR DEVALIÈRE   Some help us for a while. Some cure us entirely. No doubt, medicines—when they’re available and affordable—play a crucial role in helping us…
HAI Admin
4 February 2015

HAI Launches Innovative Global Study to Improve Access to Insulin

by MARG EWEN, Global Pricing Co-ordinator and ACCISS Study Co-investigator The global need for insulin, a hormone that converts sugar, starches and other food into needed energy for everyday activities,…
HAI Admin
16 January 2015

HAI Europe Workplan 2015

In 2015, Health Action International’s European projects team will focus research and advocacy to increase access to essential medicines, improve the rational use of medicines and promote the participation of citizens…
HAI Admin
1 January 2015

Retention of Medicines Policy in DG Health a Victory for Public Health Advocates

AMSTERDAM—Health Action International (HAI) Europe welcomes the announcement by European Commission president-elect, Jean-Claude Juncker, that health units D5 (medicinal products–authorisations, European Medicines Agency) and D6 (medicinal products–quality, safety and efficacy)…
HAI Admin
22 October 2014

Retention of Medicines Policy in DG Health a Victory for Public Health Advocates

AMSTERDAM—Health Action International (HAI) Europe welcomes the announcement by European Commission president-elect, Jean-Claude Juncker, that health units D5 (medicinal products–authorisations, European Medicines Agency) and D6 (medicinal products–quality, safety and efficacy)…
HAI Admin
22 October 2014

EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached

BRUSSELS—On 2 October 2014, the European Medicines Agency (EMA) finally adopted its policy on access to clinical data. From 1 January 2015 onwards, the general public will be able to…
HAI Admin
16 October 2014

EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached

BRUSSELS—On 2 October 2014, the European Medicines Agency (EMA) finally adopted its policy on access to clinical data. From 1 January 2015 onwards, the general public will be able to…
HAI Admin
16 October 2014

EMA policy on clinical data publication a step ahead, but falls short of true potential

by ANCEL.LA SANTOS QUINTANO (Image courtesy of pakorn / www.freedigitalphotos.net) Although it’s a step in the right direction, the European Medicines Agency’s (EMA) long-awaited clinical data publication policy—adopted on 2…
HAI Admin
15 October 2014

EU Pharmacovigilance Public Hearings Should Be As Transparent and Independent as in US

BRUSSELS—The European Medicines Agency (EMA) is finally working on the implementation of public hearings at the European Pharmacovigilance Committee, a provision included in the 2010 pharmacovigilance legislation (1). In our…
HAI Admin
14 October 2014

EU Pharmacovigilance Public Hearings Should Be As Transparent and Independent as in US

BRUSSELS—The European Medicines Agency (EMA) is finally working on the implementation of public hearings at the European Pharmacovigilance Committee, a provision included in the 2010 pharmacovigilance legislation (1). In our…
HAI Admin
14 October 2014

Trading Away Access to Medicines – Revisited

Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries. The lack of a vaccine or…
HAI Admin
29 September 2014

Trading Away Access to Medicines – Revisited

Insufficient innovation and a lack of access to affordable medicines are major barriers to achieving the right to health in low- and middle-income countries. The lack of a vaccine or…
HAI Admin
29 September 2014

Europe Seeks to Expand Big Pharma Monopoly at Expense of Poor People, Warn NGOs Ahead of TTIP Talks (2014)

The European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines, warn Oxfam and Health Action International…
HAI Admin
29 September 2014

Europe Seeks to Expand Big Pharma Monopoly at Expense of Poor People, Warn NGOs Ahead of TTIP Talks (2014)

The European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines, warn Oxfam and Health Action International…
HAI Admin
29 September 2014

Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry

by TIM REED Last week, European Commission (EC) president-elect, Jean-Claude Juncker, announced his plan to move the units responsible for pharmaceutical policy from their rightful place at DG Health to…
HAI Admin
18 September 2014

Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA

by MADALINA TRUSCA Photo courtesy of: Mehr Demokratie https://www.flickr.com/photos/mehr-demokratie/14064326877/ CC BY-SA 2.0 As the Transatlantic Trade and Investment Partnership (TTIP) negotiations between the European Union (EU) and the United States (US)…
HAI Admin
16 September 2014

Public Health in Danger with Move of Pharmaceutical Policy to DG Enterprise and Industry

Health Action International is appalled by the European Commission’s opaque and unjustified decision to move SANCO Units D5 (Medicinal Products–Authorisations, European Medicines Agency) and D6 (Medicinal Products–Quality, Safety and Efficacy)…
HAI Admin
12 September 2014

Public Health in Danger with Move of Pharmaceutical Policy to DG Enterprise and Industry

Health Action International is appalled by the European Commission’s opaque and unjustified decision to move SANCO Units D5 (Medicinal Products–Authorisations, European Medicines Agency) and D6 (Medicinal Products–Quality, Safety and Efficacy)…
HAI Admin
12 September 2014

Investor-State Dispute Settlement in EU-US Trade Deal Risks Access to Affordable Medicines

BRUSSELS—Several European and American health NGOs publicly criticised the inclusion of investor-state dispute settlement (ISDS) in the Transatlantic Trade and Investment Partnership (TTIP) today, warning that it will undermine public…
HAI Admin
14 July 2014

Investor-State Dispute Settlement in EU-US Trade Deal Risks Access to Affordable Medicines

BRUSSELS—Several European and American health NGOs publicly criticised the inclusion of investor-state dispute settlement (ISDS) in the Transatlantic Trade and Investment Partnership (TTIP) today, warning that it will undermine public…
HAI Admin
14 July 2014

EMA’s New Policy on Access to Clinical Data – About to Privatise Pharmaceutical Knowledge?

The European Medicines Agency (EMA) has made known that its controversial policy on access to clinical data is to be adopted by mid-July 2014. In the aftermath of a public…
HAI Admin
24 June 2014